Last reviewed · How we verify
NCT06088654
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1, PHASE2 trial testing IPH6501 in Non Hodgkin Lymphoma in 23 participants. Terminated before completion.
6 February 2026
Quick facts
| Lead sponsor | Innate Pharma |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 4 March 2024 |
| Primary completion | 6 February 2026 |
| Estimated completion | 6 February 2026 |
| Sites | 14 locations across France, United States, Australia |
Drugs / interventions tested
- IPH6501 — full drug profile →
Conditions studied
- Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
Sponsor
Innate Pharma — full company profile →
Who can join
18 and older, any sex, with Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06088654
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
- NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
- NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
- NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting
Other Innate Pharma trials
Trials by the same sponsor.
- NCT05321147 — Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 · Phase 1 · completed
- NCT03902184 — IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma · Phase 2 · active not recruiting
- NCT03665129 — IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors · Phase 1 · terminated
- NCT02557516 — Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06088654 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Innate Pharma
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06088654.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing